Wave PRO™ Now Commercially Available as First Unit Enters the Field
Pression has begun the commercial introduction of Wave PRO™, with the first unit now in the field with our sales team.
Following FDA clearance, this marks an important next step for Pression as we introduce Wave PRO™ to cardiologists and healthcare facilities and begin expanding awareness of a new approach to External Counterpulsation (ECP) therapy delivery.
Wave PRO™ was designed around the realities of delivering care today. Its operating model is intended to make ECP more practical to incorporate into a range of healthcare settings, with features that include:
- Minimal setup
- Autonomous operation once initiated
- Flexibility across care settings
- Compatibility with existing staffing models
- A capital-efficient approach to offering ECP therapy
The first Wave PRO™ unit in the field will allow our sales team to work directly with healthcare professionals and organizations interested in understanding the system, its design, and how it may fit within their existing programs.
For Pression, commercial availability represents the next stage in bringing Wave PRO™ from clinical development and FDA clearance into real-world use.
We believe the opportunity is not simply to introduce another ECP system, but to offer healthcare providers a different approach to how ECP therapy can be delivered.
See how Wave PRO™ approaches ECP differently — and what that could mean for your organization.
Learn more at pression.com
For use only on the order of a licensed physician. See pression.com for full prescribing and safety information.